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The Centers for Disease Control and Prevention (CDC) Quarantine Stations distribute select 
lifesaving drug products that are not commercially available or are in limited supply in the United 
States for emergency treatment of certain health conditions. Following a retrospective analysis of 
shipment records, the authors estimated an average of 6.66 hours saved per shipment when drug 
products were distributed from quarantine stations compared to a hypothetical centralized site 
from CDC headquarters in Atlanta, GA. This evaluation supports the continued use of a 
decentralized model which leverages CDC's regional presence and maximizes efficiency in the 
distribution of lifesaving drugs.
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INTRODUCTION
The Centers for Disease Control and Prevention (CDC) Drug Service program and 
Quarantine and Border Health Services Branch (QBHSB) collaborate to distribute lifesaving 
drugs for critically ill patients nationwide on a 24/7 basis. These drugs are not commercially 
available or are in limited supply in the United States. To allow the treatment of patients 
with an unlicensed drug product, the US Food and Drug Administration (FDA) may permit 
the use of a drug or biological product under an expanded access Investigational New Drug 
(IND) application. These products are intended as therapy for serious or immediately life-
threatening conditions, when no effective therapy is available commercially in the United 
States. Most are manufactured by foreign drug companies and are commercially available in 
other countries. FDA IND status is maintained by CDC so that these products are available 
in the United States, if needed. CDC provides these products free of charge to hospitals on 
an emergency basis when requested by public health officials or treating clinicians. 
However, this excludes any costs associated with the use or administration of the drug.
The CDC Drug Service distributes the majority of its products from the CDC headquarters 
in Atlanta, GA, through common courier services. Select drugs are prepositioned at nine 
CDC Quarantine Stations operated by QBHSB, which are located at major US airports. 
CDC Quarantine Stations provide strategic regional access and ensure rapid shipping of 
these lifesaving drugs. Earlier treatment can potentially make a substantial difference in the 
clinical outcomes of patients requiring these drugs.1 Evaluation is needed to confirm that the 
emergency release of lifesaving drug products from quarantine stations is an expedient 
method of delivery.
History
The CDC Drug Service was established in 1965 to serve as a vaccine bank to prevent rare 
diseases in high-risk persons. Distribution of drugs from quarantine stations on behalf of the 
CDC Drug Service began in the late 1960s. Over the last 50 years, the types of drugs 
released by quarantine stations have changed as public health systems, disease risk, and 
patient needs have changed.
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Previously, quarantine stations distributed drug products that included rifabutin, ribavirin, 
quinine, pentamidine, vaccinia immune globulin, varicella zoster immune globulin, and 
ansamycin. The distribution of these drugs was discontinued due to introduction of 
alternative therapies, decreased need for emergency distribution, or commercial availability. 
Currently, CDC Quarantine Stations release heptavalent botulinum antitoxin (HBAT), 
diphtheria antitoxin, and intravenous artesunate (for severe malaria).2,3 In March 2013, the 
FDA approved HBAT, and it is no longer considered an investigational drug.4 However, 
CDC continues to maintain the IND status as well as stockpiles of HBAT for distribution due 
to limited commercial availability of this product and in case treatment is not covered under 
the approved license.
Over the years, the number and locations of CDC Quarantine Stations that conduct 
emergency drug releases have changed. Currently, this list includes nine CDC Quarantine 
Stations located at regional gateway airports in Atlanta, Chicago, Honolulu, Houston, Los 
Angeles, Miami, New York, San Francisco, and Seattle. Drug release stations were selected 
based on staffing numbers and flight patterns that maximize geographic coverage of the 
country.
Drug product handling and distribution
The products on the CDC Drug Service formulary are available to public health officials and 
clinicians licensed in the United States when certain requirements are met.
Based on several decades of experience, CDC and state health departments have developed 
procedures for consultation prior to release of drug products. The initial request to CDC 
must be made by a state health department. This is required to ensure that the health 
department can appropriately report cases of infectious disease that are nationally notifiable 
and can conduct surveillance for additional cases. Health departments may request drug 
products by contacting the CDC Emergency Operations Center or CDC subject matter 
experts (SMEs). In addition, consultation between CDC SMEs and treating clinicians is 
required.
If the requested drug is one distributed by QBHSB, a CDC SME will authorize the nearest 
quarantine station to release the drug to the requesting healthcare facility. If air transport is 
required, quarantine station staff will package the drug for shipment on the next available 
flight. For ground transportation, coordination with couriers, law enforcement, or other 
agency personnel may be needed. The receiving healthcare facility is responsible for 
retrieving the drug package from either the quarantine station or the destination airport, or 
arranging ground transportation. CDC tracks the arrival of the package.
The drug products are temperature sensitive; therefore, cold chain management must be 
preserved during storage and throughout the shipping process. Drug products are packaged 
with an insert that includes full prescribing information approved by the FDA, along with 
any other instructions for the pharmacy and treating clinician. Treating clinicians must 
comply with the approved IND protocol and notify CDC of any adverse events that occur 
during or after drug administration. Unused drug products are returned to the CDC Drug 
Service.
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PURPOSE
To evaluate the operational efficiency of the CDC Quarantine Stations' emergency drug 
release activity, we retrospectively analyzed drug release records for a 2-year period. In 
addition, we compared actual delivery time for a subset of the shipments with a hypothetical 
estimate of the time it would have taken to ship the drug from the CDC headquarters in 
Atlanta, GA.
METHODS
Drug release records were obtained from CDC's Quarantine Activity Reporting System 
(QARS) for October 1, 2010 through September 30, 2012. QARS is a secure web-based 
system which allows quarantine station personnel to record station activities, including drug 
release requests. Variables included the date and time of the request, drug requested and 
number of doses, requesting location, responding quarantine station, method of delivery, 
arrival time, patient age and sex, clinical outcome, and drug disposition. SAS version 9.2 
software (SAS Institute Inc., Cary, NC) was used to conduct descriptive analyses.
To assess the effectiveness of the decentralized model of drug releases from quarantine 
stations, we compared the actual delivery times to estimated delivery times from a 
hypothetical situation where drug releases occurred from the CDC headquarters in Atlanta. 
Drug releases from January 1, 2012 to September 30, 2012 were used for this portion of the 
analysis. Drug releases from the Atlanta Quarantine Station were excluded from this portion 
of the analysis because delivery times were not likely to be appreciably different than those 
from the CDC headquarters.
For shipments from CDC headquarters, we estimated that it would take approximately 4 
hours from the time of SME authorization to shipment departure on a commercial flight 
from Atlanta, GA. This estimate allowed time for station staff commuting from home to 
CDC headquarters, packaging the shipment, driving to the Atlanta airport, processing the 
package at the cargo facility, and meeting airline deadline requirements for package 
submission prior to flight departure. As historical flight data were not available, we used 
GoogleFlights (www.google.com/flights) to search for current flights departing from Atlanta 
at least 4 hours after the request time and arriving at the airport closest to the requesting 
location. Flights during the same month and day of the week as the actual drug release and 
with the earliest arrival time were selected.
Actual delivery time was calculated by subtracting the request time from the arrival time as 
recorded in QARS. Time for delivery from CDC headquarters was calculated by subtracting 
the request time recorded in QARS from the arrival time of the selected flight. A paired t-
test was used to evaluate for a significant difference between actual delivery time and 
estimated delivery time from CDC headquarters. Actual delivery time was subtracted from 
estimated delivery time to determine if time was saved.
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RESULTS
From October 1, 2010 to September 30, 2012, CDC Quarantine Stations received a total of 
287 requests for emergency drug releases: 173 (60 percent) for HBAT, 105 (37 percent) for 
artesunate, and 9 (3 percent) for diphtheria antitoxin. Drug type requested varied 
considerably by responding quarantine station (Figure 1).
One hundred fifty-two (53 percent) of drug releases were delivered by airplane. The 
remaining 135 (47 percent) were delivered by helicopter or ground transportation, including 
retrieval by hospital personnel or delivery by law enforcement or courier services. Ground 
transportation was primarily used when the requesting location was within 100 miles of the 
responding quarantine station. One hundred fifty-four (54 percent) of drug requests were 
made outside regular quarantine station operating hours.
Most US states (78 percent) received at least one drug release during the evaluation period. 
California had the highest number of drug release requests, accounting for 28 percent of all 
releases during the evaluation period. Five states (California, New York, Texas, Florida, and 
Washington) accounted for more than half of all drug releases; each of these has at least one 
quarantine station that currently distributes drugs.
Patient sex was known for 278 (97 percent) of patients; of those 65 percent were male. Age 
was known for 268 (93 percent) of patients; the median age was 44 years (range, 9 months 
to 85 years). Outcome data were known for 183 (64 percent) of the releases; of those 174 
(95 percent) improved or recovered and 9 (5 percent) died (Figure 2). Type of botulism 
infection was known for 101 (58 percent) of the HBAT drug releases; 63 (62 percent) were 
wound botulism and 38 (38 percent) foodborne.
Ninety-four drug releases occurred from January 1, 2012 to September 30, 2012. This subset 
of releases was further studied for differences between the actual delivery time and an 
estimated hypothetical delivery time from CDC headquarters. Ten records were omitted 
from the analysis, five that were incomplete and five that were releases from the Atlanta 
Quarantine Station. For the remaining 84 records, the overall mean difference in delivery 
time for shipments from quarantine stations compared with CDC headquarters was 6.66 
hours faster from quarantine stations (median of 6.00 hours, p < 0.0001). Delivery from 
quarantine stations was significantly faster for 74 (88 percent), with a mean time difference 
of 8.26 hours (median of 6.87 hours, p < 0.0001). For 10 releases (12 percent), delivery from 
CDC headquarters was faster, with a mean time difference of 5.19 hours (median of 2.78 
hours).
DISCUSSION
The prepositioning of lifesaving drug products at quarantine stations results in the rapid 
distribution of medical treatment for critically ill patients. Our analysis indicated that 
prepositioning drugs at CDC Quarantine Stations reduced distribution time by an average of 
about 7 hours when compared to an estimated hypothetical centralized distribution site from 
the CDC headquarters in Atlanta, GA. This suggests that the decentralized model facilitated 
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more timely availability of treatment for critically ill patients with foodborne or wound 
botulism, diphtheria, or malaria.
Our analysis also found that CDC's emergency drug release caches are appropriately 
positioned geographically. The top five states requesting emergency drug releases accounted 
for more than half of all drug requests; at least one drug-releasing quarantine station is 
located within each of these states. The finding that close to half of all shipments were 
delivered via ground transportation further suggests that stations are well positioned. Two 
states that do not have quarantine stations, Utah and Arizona, received a high volume of 
releases during the evaluation period; however, these requests were related to outbreaks of 
botulism in incarcerated populations and did not reflect frequent or repeated emergency drug 
release requests.5
This evaluation identified several areas for program improvement. Certain QARS data 
elements including drug request and arrival times could be further refined and standardized. 
Patient outcome data were unavailable for more than a third of the drug releases. Enhanced 
collaboration with SMEs, hospital providers, and public health partners may help increase 
the quality of outcome data. This could enhance future analyses to determine if time saved 
by the decentralized model of drug distribution contributes to a reduction in morbidity and 
mortality.
Due to limited supplies and regulatory and logistical requirements, CDC is unable to 
preposition drug products in every community. CDC Quarantine Stations provide strategic 
regional access and ensure that the drug product supply is properly maintained, shipped, and 
tracked. The selected quarantine station locations provide maximum geographic coverage 
nationwide.
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Figure 1. 
Centers for Disease Control and Prevention (CDC) drug releases by drug type and 
responding quarantine station, October 1, 2010 to September 30, 2012 (N = 287).
Roohi et al. Page 8
J Emerg Manag. Author manuscript; available in PMC 2018 February 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
CDC Quarantine Station drug releases by drug released and reported patient outcome, 
October 1, 2010 to September 30, 2012 (N = 287).
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